search
Back to results

Adjunctive Treatment for Chronic Rhinosinusitis With Nasal Polyposis

Primary Purpose

Chronic Rhinosinusitis, Nasal Polyps

Status
Not yet recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Triamcinolone-impregnated CMC foam
Propel Stent
Sponsored by
Marina Boruk
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Rhinosinusitis

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Diagnosis of nasal polyposis and desiring surgery

Exclusion Criteria:

  • A known history of intolerance to corticosteroids
  • An oral steroid-dependent condition
  • A history of immune deficiency
  • Pre-existing narrow angle glaucoma or cataracts
  • Subjects that did not complete the pre-op medical regimen described below
  • Pregnant and/or breastfeeding

Sites / Locations

  • SUNY Downstate Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Steroid-eluting implant (Propel)

Triamcinolone-impregnated CMC foam

Arm Description

Mometasone furoate implant. 370ug of mometasone furoate with each application. One application to be used at the conclusion of surgery and left in place for 1 month or less depending on if it requires removal during office debridement.

Applied to one nostril at end of case through randomization. Experimental drug is triamcinolone-acetonide 40mg/mL. 2mL will be combined with 5mL sterile water and mixed with carboxymethylcellulose foam and placed in the nares at the conclusion of the surgery. This will only be applied once and will remain in the nares until it dissolves or 7 days.

Outcomes

Primary Outcome Measures

Postoperative Perioperative Sinus Endoscopy Score
The Perioperative Sinus Endoscopy score sums the combined scores determined from middle turbinate position, middle meatal status, ethmoid cavity appearance, as well as secondary sinus blockage (frontal and sphenoid). Each category is scored from 0-2, with 0 being not present, 1 as partially present, and 2 being fully present. The highest total score is 16, with scores ranging from 18-20 when the frontal and sphenoid sinuses are also included. The higher the score, the worse the status of the nasal cavity. Comparison of the mean POSE scores for the two treatments at day 30 to determine there is noninferiority

Secondary Outcome Measures

Full Information

First Posted
July 23, 2018
Last Updated
July 31, 2023
Sponsor
Marina Boruk
Collaborators
State University of New York - Downstate Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT03607175
Brief Title
Adjunctive Treatment for Chronic Rhinosinusitis With Nasal Polyposis
Official Title
Randomized Clinical Control Trial Comparing the Effects of a Steroid Eluting Implant Versus Triamcinolone-impregnated Carboxymethylcellulose Foam on the Postoperative Clinic Experience in Patients That Underwent Functional Endoscopic Surgery for Nasal Polyposis
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
July 24, 2023 (Anticipated)
Primary Completion Date
September 30, 2025 (Anticipated)
Study Completion Date
December 30, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Marina Boruk
Collaborators
State University of New York - Downstate Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a research study to find out if an off-label use of carboxymethylcellulose foam (CMC), an absorbable nasal packing, combined with triamcinolone acetonide, a steroid, is more comfortable postoperatively for participants and is as effective in decreasing scarring, swelling and crusting after surgery than an FDA approved steroid eluting implant. Anticipated sample size will be 30. Study is an intrapatient control design. Subjects will be randomly assigned to receive CMC foam with triamcinolone in one nare and the steroid-eluting implant in the other. Participants will fill out preoperative and follow-up visit surveys at 7, 14, 30 and 90 days. Subjects at each visit will also have pictures taken of the nasal cavities to be scored for later analysis. Paired t-tests will be performed for analysis. Our primary objective is to demonstrate that triamcinolone-impregnated carboxymethylcellulose foam is noninferior to steroid-eluting implants in improving postoperative ethmoid inflammation, middle turbinate position, preventing intranasal synechiae and reducing polypoid change with objective measurement scales Our secondary objects include assessing the quality-of-life and nasal obstruction symptoms before and after functional endoscopic sinus surgery with validated SNOT-22 and NOSE questionnaires and to assess the cost-effectiveness of triamcinolone-impregnated carboxymethylcellulose foam versus steroid-eluting implant in management of CRSwNP in the early postoperative period. The endpoints are the POSE scores, the SNOT-22 and NOSE scores at days 7, 14, 30 and 90.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Rhinosinusitis, Nasal Polyps

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Model Description
Study is an intrapatient control design, each subject will receive both interventions, one in each nostril
Masking
ParticipantOutcomes Assessor
Masking Description
Participants and outcomes assessor will be blinded to the side that the steroid eluting implant and the triamcinolone-impregnated foam in on.
Allocation
Randomized
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Steroid-eluting implant (Propel)
Arm Type
Active Comparator
Arm Description
Mometasone furoate implant. 370ug of mometasone furoate with each application. One application to be used at the conclusion of surgery and left in place for 1 month or less depending on if it requires removal during office debridement.
Arm Title
Triamcinolone-impregnated CMC foam
Arm Type
Experimental
Arm Description
Applied to one nostril at end of case through randomization. Experimental drug is triamcinolone-acetonide 40mg/mL. 2mL will be combined with 5mL sterile water and mixed with carboxymethylcellulose foam and placed in the nares at the conclusion of the surgery. This will only be applied once and will remain in the nares until it dissolves or 7 days.
Intervention Type
Drug
Intervention Name(s)
Triamcinolone-impregnated CMC foam
Other Intervention Name(s)
Kenalog-40
Intervention Description
same information as included in the arm/group descriptions
Intervention Type
Device
Intervention Name(s)
Propel Stent
Intervention Description
same information as included in the arm/group descriptions
Primary Outcome Measure Information:
Title
Postoperative Perioperative Sinus Endoscopy Score
Description
The Perioperative Sinus Endoscopy score sums the combined scores determined from middle turbinate position, middle meatal status, ethmoid cavity appearance, as well as secondary sinus blockage (frontal and sphenoid). Each category is scored from 0-2, with 0 being not present, 1 as partially present, and 2 being fully present. The highest total score is 16, with scores ranging from 18-20 when the frontal and sphenoid sinuses are also included. The higher the score, the worse the status of the nasal cavity. Comparison of the mean POSE scores for the two treatments at day 30 to determine there is noninferiority
Time Frame
30 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Provision of signed and dated informed consent form Stated willingness to comply with all study procedures and availability for the duration of the study Diagnosis of nasal polyposis and desiring surgery Exclusion Criteria: A known history of intolerance to corticosteroids An oral steroid-dependent condition A history of immune deficiency Pre-existing narrow angle glaucoma or cataracts Subjects that did not complete the pre-op medical regimen described below Pregnant and/or breastfeeding
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Marina Boruk, MD
Phone
646-481-1311
Email
marina.boruk@downstate.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Matthew D Adams, MD
Phone
814-592-5634
Email
matthew.adams@downstate.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marina Boruk, MD
Organizational Affiliation
SUNY Downstate Med Ctr
Official's Role
Principal Investigator
Facility Information:
Facility Name
SUNY Downstate Medical Center
City
Brooklyn
State/Province
New York
ZIP/Postal Code
11203
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marina Boruk, MD
Phone
646-481-1311
Email
marina.boruk@downstate.edu
First Name & Middle Initial & Last Name & Degree
Matthew D Adams, MD
Phone
814-592-5634
Email
matthew.adams@downstate.edu

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Adjunctive Treatment for Chronic Rhinosinusitis With Nasal Polyposis

We'll reach out to this number within 24 hrs